AN2 Therapeutics Past Earnings Performance
Past criteria checks 0/6
AN2 Therapeutics's earnings have been declining at an average annual rate of -23.5%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually.
Key information
-23.5%
Earnings growth rate
45.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -51.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01Revenue & Expenses BreakdownBeta
How AN2 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -65 | 15 | 55 |
| 30 Sep 23 | 0 | -60 | 15 | 49 |
| 30 Jun 23 | 0 | -54 | 14 | 43 |
| 31 Mar 23 | 0 | -49 | 15 | 36 |
| 31 Dec 22 | 0 | -43 | 13 | 30 |
| 30 Sep 22 | 0 | -40 | 11 | 27 |
| 30 Jun 22 | 0 | -38 | 9 | 23 |
| 31 Mar 22 | 0 | -35 | 6 | 21 |
| 31 Dec 21 | 0 | -28 | 5 | 17 |
| 31 Dec 20 | 0 | -15 | 1 | 6 |
Quality Earnings: ANTX is currently unprofitable.
Growing Profit Margin: ANTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANTX is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare ANTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: ANTX has a negative Return on Equity (-51.91%), as it is currently unprofitable.